Percheron Therapeutics

Default features description for sign up page.

PATIENTS

HMBD-002

PIPELINE

WHY INVEST

ASX ANNOUNCEMENTS

UPDATES

CORPORATE GOVERNANCE

PARTNERSHIPS & COLLABORATORS

MEET THE TEAM

CORPORATE DIRECTORY

ABOUT

HOME

Titillium Web

Dr James Garner, CEO of Percheron Therapeutics (ASX:PER) provides an update on the company's new lead candidate, a cancer immunotherapy drug called HMBD-002, which it just in-licensed from Singapore's Hummingbird Bioscience.

This drug has completed a 48-patient Phase 1 across multiple tumour types. The drug has an excellent safety profile, with no dose limiting toxicities reached and only a modest level of treatment-related adverse events, and several patients showed encouraging duration of response.

Percheron Therapeutics is excited about the potential for this drug given what is known about its target, the immune checkpoint VISTA. At the moment you can buy Percheron Therapeutics for about cash backing.

Stocks Down Under 🎥 | Interview with CEO Dr James Garner